Dr. William Yang, M.D.
Nephrology (Kidney) (Nephrology Physician)
18433 Roscoe Blvd, Suite #202
Northridge, CA 91325
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 17
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 933
Licensed in California since 2012, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
CA license A120820 (first issued 2012; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Northridge Hospital Medical Center Northridge, CA
Medical groups
- Renal Consultants Medical Group (9 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 933
- Services billed
- 9,136
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 1,652 | 329 |
| Established patient office or other outpatient visit, 40-54 minutes | 849 | 337 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 799 | 140 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 740 | 155 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 572 | 123 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 357 | 162 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 353 | 309 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 150 | 28 |
| Critical care, first 30-74 minutes | 129 | 40 |
| Complete ultrasound scan behind abdominal cavity | 120 | 119 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Amlodipine Besylate Other prescribers in Northridge, CA | 240 |
| Losartan Potassium Other prescribers in Northridge, CA | 224 |
| Nifedipine Er (nifedipine) Other prescribers in Northridge, CA | 186 |
| Kerendia (finerenone) Other prescribers in Northridge, CA | 170 |
| Torsemide Other prescribers in Northridge, CA | 170 |
| Allopurinol Other prescribers in Northridge, CA | 149 |
| Doxazosin Mesylate Other prescribers in Northridge, CA | 142 |
| Jardiance (empagliflozin) Other prescribers in Northridge, CA | 138 |
| Atorvastatin Calcium Other prescribers in Northridge, CA | 118 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Northridge, CA | 117 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 17 companies reported 137 payments worth $12,527 in total to this clinician.
| Bayer HealthCare Pharmaceuticals Inc. | $7,913 |
|---|---|
| Scpharmaceuticals Inc. | $2,040 |
| Amgen Inc. | $561 |
| AstraZeneca Pharmaceuticals LP | $507 |
| Otsuka America Pharmaceutical, Inc. | $323 |
| Novartis Pharmaceuticals Corporation | $303 |
| Akebia Therapeutics Inc | $181 |
| Vifor Pharma, Inc. | $161 |
| Compensation for services other than consulting (speaking, faculty) | $7,380 |
|---|---|
| Food and Beverage | $3,100 |
| Honoraria | $2,000 |
| Travel and Lodging | $28.00 |
| Education | $18.71 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. May 16, 2025 | Compensation for services other than consulting (speaking, faculty) Kerendia · Cardio-Renal | $2,255 |
| Scpharmaceuticals Inc. Dec 2, 2025 | Honoraria FUROSCIX · Cardiology | $2,000 |
| Bayer HealthCare Pharmaceuticals Inc. Mar 5, 2025 | Compensation for services other than consulting (speaking, faculty) Kerendia · Cardio-Renal | $1,640 |
| Bayer HealthCare Pharmaceuticals Inc. Sep 22, 2025 | Compensation for services other than consulting (speaking, faculty) Kerendia · Cardio-Renal | $1,640 |
| Bayer HealthCare Pharmaceuticals Inc. May 16, 2025 | Compensation for services other than consulting (speaking, faculty) Kerendia · Cardio-Renal | $1,230 |
| Bayer HealthCare Pharmaceuticals Inc. Feb 1, 2025 | Compensation for services other than consulting (speaking, faculty) Kerendia · Cardio-Renal | $615 |
| Bayer HealthCare Pharmaceuticals Inc. May 21, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to Oxnard, CA · in-kind | $28.00 |
| Vifor Pharma, Inc. May 12, 2025 | Education in-kind | $12.00 |
| Amgen Inc. Oct 15, 2025 | Education KRYSTEXXA · Inflammation/Rare Disease · in-kind | $6.71 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $93,774 in research payments for these studies, mostly to the institutions running them.
- A phase I and IIa randomized,double blind,placebo controlled study to evaluate the safety and pharmacokinetics of AZD7760 in healthy participants and in patients with end stage kidney disease receiving hemodialysis th…
AstraZeneca Pharmaceuticals LP - BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic
Bayer HealthCare Pharmaceuticals Inc. - BAY 948862, Clinical characteristics, treatment patterns and outcomes of patients treated with Finerenone in routine clinical practice A prospective non-interventional study.
Bayer HealthCare Pharmaceuticals Inc. - BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chron…
Bayer HealthCare Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.